Symplast lands growth financing from Level Structured Capital

By AI, Created 4:41 PM UTC, May 18, 2026, /AGP/ – Symplast said May 13 it secured growth financing from Level Structured Capital to speed commercial expansion after a 2026 Best in KLAS win for Ambulatory Plastic Surgery Solutions. The funding will support sales, go-to-market efforts and product innovation as the aesthetic medicine software vendor pushes deeper into the specialty.

Why it matters: - Symplast is using new capital to try to convert product momentum into broader market share in aesthetic medicine software. - The financing supports expansion in a cash-pay healthcare niche where specialized software can shape practice efficiency, patient experience and revenue growth. - The deal follows a 2026 Best in KLAS recognition, which can help validate the platform with buyers in a competitive market.

What happened: - Symplast announced growth financing from Level Structured Capital, a business unit of Level Equity, on May 13, 2026. - The company said the capital will fund commercial and go-to-market expansion. - Symplast also tied the announcement to the launch of two campaigns, Beautiful Business and You Deserve the Best, debuting at The Aesthetic Meet 2026.

The details: - Symplast describes itself as a mobile-first, cloud-based, AI-powered practice management platform built exclusively for plastic surgeons and aesthetic medicine practices. - The platform covers EHR, practice management, CRM, payments, AI and growth services in one system. - Symplast said the financing will help scale the sales organization and deepen its presence inside The Aesthetic Society and the broader specialty. - The company said the new capital will also amplify the Beautiful Business and You Deserve the Best campaigns. - Symplast said it will continue investing in product innovation, including AI-powered workflows and new tools for aesthetic medicine practices. - The company said its 2026 Best in KLAS recognition for Ambulatory Plastic Surgery Solutions validates long-held customer feedback. - Symplast also said it is a Premier Technology Partner of The Aesthetic Society. - Level Structured Capital said customer reference calls, practice testimonials and Symplast’s position in the market helped shape the investment decision. - Level Structured Capital is a software-focused investor backing vertical SaaS companies through growth phases. - Level Equity said it was founded in 2009, has $6.4 billion in assets under management and has made more than 125 investments. - Level Equity said its in-house value creation engine is called NextLevel Operations.

Between the lines: - The financing signals confidence in specialty software built for a narrow vertical rather than a general-purpose healthcare platform. - Symplast is leaning on both awards and customer advocacy to support its positioning as the category leader. - The launch of the two campaigns suggests the company wants to pair operational scale with brand visibility.

What’s next: - Symplast will use the capital to expand sales and marketing reach across aesthetic medicine. - The company plans to keep investing in AI-driven product development. - Symplast said the partnership will help bring its platform to more aesthetic practices that want an integrated operating system. - The company’s next phase appears focused on turning recognition and product maturity into wider adoption.